Evidence map›Paper›PMID 38922667›Full record

ArticleJMIR aging2024

Examining Associations Between Smartphone Use and Clinical Severity in Frontotemporal Dementia: Proof-of-Concept Study.

Emily W Paolillo, Kaitlin B Casaletto, Annie L Clark, Jack C Taylor, Hilary W Heuer, Amy B Wise, Sreya Dhanam, Mark Sanderson-Cimino, Rowan Saloner, Joel H Kramer and 40 more

Abstract read
In one paragraph

Article in JMIR aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Developing digital health technologies for frontotemporal degeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

50 authors.

Emily W PaolilloDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0003-4188-6998
Kaitlin B CasalettoDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0001-5000-7604
Annie L ClarkDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0009-0008-1609-2540
Jack C TaylorDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-6431-9956
Hilary W HeuerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-3776-1685
Amy B WiseDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0009-0000-8828-456X
Sreya DhanamDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0009-0000-3194-2170
Mark Sanderson-CiminoDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-5872-3186
Rowan SalonerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-1351-6183
Joel H KramerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-2917-8297
John KornakDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-0089-0619
Walter KremersDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0000-0001-5714-3473
Leah ForsbergDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0000-0003-4086-9598
Brian ApplebyDepartment of Neurology, Case Western Reserve University, Cleveland, OH, United States.ORCID https://orcid.org/0000-0003-2275-3292
Ece BayramDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, United States.ORCID https://orcid.org/0000-0002-6875-4242
Andrea BozokiDepartment of Neurology, University of North Carolina, Chapel Hill, NC, United States.ORCID https://orcid.org/0000-0002-4899-9381
Danielle BrushaberDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0009-0007-0543-0228
R Ryan DarbyDepartment of Neurology, Vanderbilt University, Nashville, TN, United States.ORCID https://orcid.org/0000-0003-0326-1268
Gregory S DayDepartment of Neurology, Mayo Clinic, Jacksonville, FL, United States.ORCID https://orcid.org/0000-0001-5133-5538
Bradford C DickersonDepartment of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.ORCID https://orcid.org/0000-0002-5958-3445
Kimiko Domoto-ReillyDepartment of Neurology, University of Washington, Seattle, WA, United States.ORCID https://orcid.org/0000-0002-7396-1633
Fanny ElahiDepartment of Neurology, The Deane Center for Wellness and Cognitive Health, Icahn School of Medicine at Mount Sinai, New York, NY, United States.ORCID https://orcid.org/0000-0003-4663-4992
Julie A FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0000-0002-1282-9866
Nupur GhoshalDepartment of Neurology, Knight Alzheimer's Disease Research Center, Washington University, St. Louis, MO, United States.ORCID https://orcid.org/0000-0002-6680-6731
Neill Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, FL, United States.ORCID https://orcid.org/0000-0001-9847-9096
Matthew G H HallDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0001-5077-6526
Lawrence S HonigDepartment of Neurology, Columbia University, New York, NY, United States.ORCID https://orcid.org/0000-0002-9703-2265
Edward D HueyDepartment of Psychiatry and Human Behavior, Brown University, Providence, RI, United States.ORCID https://orcid.org/0000-0002-8295-5884
Maria I LapidDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0000-0002-1163-5584
Irene LitvanDepartment of Neurosciences, University of California, San Diego, La Jolla, CA, United States.ORCID https://orcid.org/0000-0002-3485-3445
Ian R MackenzieDepartment of Pathology, University of British Columbia, Vancouver, BC, Canada.ORCID https://orcid.org/0000-0003-3875-2972
Joseph C MasdeuStanley H. Appel Department of Neurology, Nantz National Alzheimer Center, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.ORCID https://orcid.org/0000-0001-9955-6954
Mario F MendezDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.ORCID https://orcid.org/0000-0001-6441-7989
Carly MesterDepartment of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0000-0002-5863-946X
Toji MiyagawaDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0000-0002-9387-0253
Georges NaasanDepartment of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.ORCID https://orcid.org/0000-0002-6505-630X
Belen PascualStanley H. Appel Department of Neurology, Nantz National Alzheimer Center, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX, United States.ORCID https://orcid.org/0000-0002-4467-7406
Peter PressmanDepartment of Neurology, University of Colorado, Aurora, CO, United States.ORCID https://orcid.org/0000-0003-1760-1286
Eliana Marisa RamosDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.ORCID https://orcid.org/0009-0003-7982-4415
Katherine P RankinDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-3611-0848
Jessica RexachDepartment of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.ORCID https://orcid.org/0000-0002-4462-7249
Julio C RojasDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-1308-646X
Lawren VandeVredeDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-8304-6711
Bonnie WongDepartment of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.ORCID https://orcid.org/0000-0001-9973-3009
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL, United States.ORCID https://orcid.org/0000-0001-5487-1053
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, United States.ORCID https://orcid.org/0000-0002-4153-8187
Howard J RosenDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0001-9281-7402
Adam L BoxerDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-1215-5064
Adam M StaffaroniDepartment of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, United States.ORCID https://orcid.org/0000-0002-3903-9805
ALLFTD Consortium *see Acknowledgements, San Francisco, CA, United States.

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER, Bradley F Boeve · 2019 to 2026
$120.9M
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8M
NATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
Research Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Serggio Carlo Lanata · 2019 to 2026
$36.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI Walter K. Kremers · 2019 to 2026
$33.5M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI NIKOLAOS K ROBAKIS · 2020 to 2026
$31.0M
University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI SUMAN JAYADEV · 2020 to 2026
$29.0M
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of DiseaseU01NS120901 · NINDS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stacey Lynn Clardy · 2021 to 2026
$19.6M
The Four Repeat Tauopathy Neuroimaging InitiativeR01AG038791 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BOXER, ADAM L. · 2010 to 2020
$18.1M
CSRD VA IK2 CX002180NIA NIH HHS K23 AG059888NIA NIH HHS K23 AG061253NIA NIH HHS K23 AG064029NIA NIH HHS K23 AG073514NIA NIH HHS K24 AG045333NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066514NIA NIH HHS R01 AG032289NIA NIH HHS R01 AG032306NIA NIH HHS R01 AG038791NIA NIH HHS R01 AG058233NIA NIH HHS R01 AG077557NIA NIH HHS RF1 AG032289NIA NIH HHS RF1 AG077557NIA NIH HHS U01 AG016976NIA NIH HHS U01 AG045390NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG032438NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG021886NINDS NIH HHS K08 NS105916NINDS NIH HHS R01 NS050915NINDS NIH HHS R21 NS114764NINDS NIH HHS R25 NS098999NINDS NIH HHS R56 NS050915NINDS NIH HHS RF1 NS050915NINDS NIH HHS U01 NS100610NINDS NIH HHS U01 NS120901NINDS NIH HHS U54 NS092089
6 · The paper itself

Abstract

backgroundFrontotemporal lobar degeneration (FTLD) is a leading cause of dementia in individuals aged <65 years. Several challenges to conducting in-person evaluations in FTLD illustrate an urgent need to develop remote, accessible, and low-burden assessment techniques. Studies of unobtrusive monitoring of at-home computer use in older adults with mild cognitive impairment show that declining function is reflected in reduced computer use; however, associations with smartphone use are unknown.

objectiveThis study aims to characterize daily trajectories in smartphone battery use, a proxy for smartphone use, and examine relationships with clinical indicators of severity in FTLD.

methodsParticipants were 231 adults (mean age 52.5, SD 14.9 years; n=94, 40.7% men; n=223, 96.5% non-Hispanic White) enrolled in the Advancing Research and Treatment of Frontotemporal Lobar Degeneration (ARTFL study) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS study) Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Mobile App study, including 49 (21.2%) with mild neurobehavioral changes and no functional impairment (ie, prodromal FTLD), 43 (18.6%) with neurobehavioral changes and functional impairment (ie, symptomatic FTLD), and 139 (60.2%) clinically normal adults, of whom 55 (39.6%) harbored heterozygous pathogenic or likely pathogenic variants in an autosomal dominant FTLD gene. Participants completed the Clinical Dementia Rating plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Behavior and Language Domains (CDR+NACC FTLD) scale, a neuropsychological battery; the Neuropsychiatric Inventory; and brain magnetic resonance imaging. The ALLFTD Mobile App was installed on participants' smartphones for remote, passive, and continuous monitoring of smartphone use. Battery percentage was collected every 15 minutes over an average of 28 (SD 4.2; range 14-30) days. To determine whether temporal patterns of battery percentage varied as a function of disease severity, linear mixed effects models examined linear, quadratic, and cubic effects of the time of day and their interactions with each measure of disease severity on battery percentage. Models covaried for age, sex, smartphone type, and estimated smartphone age.

resultsThe CDR+NACC FTLD global score interacted with time on battery percentage such that participants with prodromal or symptomatic FTLD demonstrated less change in battery percentage throughout the day (a proxy for less smartphone use) than clinically normal participants (P<.001 in both cases). Additional models showed that worse performance in all cognitive domains assessed (ie, executive functioning, memory, language, and visuospatial skills), more neuropsychiatric symptoms, and smaller brain volumes also associated with less battery use throughout the day (P<.001 in all cases).

conclusionsThese findings support a proof of concept that passively collected data about smartphone use behaviors associate with clinical impairment in FTLD. This work underscores the need for future studies to develop and validate passive digital markers sensitive to longitudinal clinical decline across neurodegenerative diseases, with potential to enhance real-world monitoring of neurobehavioral change.

Indexed as

Frontotemporal DementiaSmartphoneAdultAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedMobile ApplicationsNeuropsychological TestsProof of Concept StudySeverity of Illness Indexclinical trialscognitioncognitive impairmentdigitalmobile phonemonitoringneurodegenerativeneuropsychologyremotescreeningtechnology

Identifiers

PMID38922667
PMCPMC11237775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.